Produkt
KlappentextThe second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and sarcomas, showcasing advances in the management of cancer broadly classified as hematological malignancies, solid tumors and tumors arising in the connective tissue. Scientists, oncologists and advanced students will be provided with knowledge of basic immunology in the context of tumor biology, providing a comprehensive overview of the cellular components of the immune system that interact with each other to provide a successful immune response. A number of new, scientific findings in his fast moving field have necessitated a thoroughly updated and revised edition including the use of immunotherapy for gastrointestinal and genitourinary cancers, as well as discussions on optimizing radiotherapy with immunotherapeutic approaches, biomarkers of response or resistance to immunotherapy, cancer imaging in immunotherapy, skin reactions to immune checkpoint inhibitors and more.
As immunotherapeutic agents differ significantly from chemotherapeutic agents in response patterns and toxicity profiles, evaluating their safety and efficacy in clinical trials remains a challenge. The new edition will discuss the use of a variety of traditional and new immunotherapy criteria to evaluate response, their inadequacies and clinical implications. Additionally, the book will outline how new advances in medical imaging technology has the potential to provide high-dimensional data to improve decision support and individualize treatment selection and monitoring.
Edited by two renowned experts in the field, the book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
Dr. Aung Naing is an Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing's research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.
Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children's Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Early Career Immunologist Committee at the Clinical Immunology Society.
Dr. Hajjar serves as a reviewer for the Journal of Clinical Immunology, Journal of General Internal Medicine and Allergy and Asthma Proceedings. She has received travel awards to present her research at the Clinical Immunology Society, American Academy of Allergy, Asthma and Immunology, and the American College of Allergy, Asthma and Immunology national meetings.
Dr. Hajjar's research interests are in primary immunodeficiency disorders, and cancer immunotherapy.
As immunotherapeutic agents differ significantly from chemotherapeutic agents in response patterns and toxicity profiles, evaluating their safety and efficacy in clinical trials remains a challenge. The new edition will discuss the use of a variety of traditional and new immunotherapy criteria to evaluate response, their inadequacies and clinical implications. Additionally, the book will outline how new advances in medical imaging technology has the potential to provide high-dimensional data to improve decision support and individualize treatment selection and monitoring.
Edited by two renowned experts in the field, the book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
Dr. Aung Naing is an Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing's research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.
Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children's Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Early Career Immunologist Committee at the Clinical Immunology Society.
Dr. Hajjar serves as a reviewer for the Journal of Clinical Immunology, Journal of General Internal Medicine and Allergy and Asthma Proceedings. She has received travel awards to present her research at the Clinical Immunology Society, American Academy of Allergy, Asthma and Immunology, and the American College of Allergy, Asthma and Immunology national meetings.
Dr. Hajjar's research interests are in primary immunodeficiency disorders, and cancer immunotherapy.
Details
Weitere ISBN/GTIN9783030025052
ProduktartE-Book
EinbandartE-Book
FormatPDF
Format Hinweis1 - PDF Watermark
FormatE107
Erscheinungsjahr2018
Erscheinungsdatum11.12.2018
Auflage2nd ed. 2018
Reihen-Nr.995
Seiten182 Seiten
SpracheEnglisch
IllustrationenVIII, 182 p. 503 illus., 17 illus. in color.
Artikel-Nr.4070344
Rubriken
Genre9200